The Effects of the Fanconi Anemia Zinc Finger (FAZF) on Cell Cycle, Apoptosis, and Proliferation Are Differentiation Stage-specific*

Mu-Shui Dai‡§¶, Nathalie Chevallier‡, Stacie Stone‡, Michael C. Heinrich**‡‡, Melanie McConnell, Tanja Reuter‡, Hal E. Broxmeyer‡, Jonathan D. Licht‡, Li Lu§, and Maureen E. Hoatlin‡§§

From the ‡Division of Molecular Medicine, Oregon Health and Science University, Portland, Oregon 97201, §Department of Microbiology/Immunology and the Walther Oncology Center, Indiana University School of Medicine and the Walther Cancer Institute, Indianapolis, Indiana 46202, ¶Derald H. Ruttenberg Cancer Center and Department of Medicine, The Mount Sinai School of Medicine, New York, New York 10029, and **Division of Hematology and Medical Oncology, Department of Medicine and the Portland Veterans Administration Medical Center, Portland, Oregon 97201

FAZF, a member of the BTB/POZ family of transcriptional repressor proteins, has been shown to bind to FANCC, the protein defective in patients with the bone marrow failure syndrome Fanconi anemia complementation group C. Because bone marrow failure in Fanconi anemia has been attributed to a failure of the hematopoietic stem cell population to produce sufficient progeny, we documented the expression of FAZF in human CD34+ hematopoietic progenitor cells. FAZF was expressed at high levels in early stages of differentiation but declined during subsequent differentiation into erythroid and myeloid lineages. Consistent with its presumed role as a transcriptional repressor, FAZF was found in the nuclear compartment, where it resides in distinct nuclear speckles at or near sites of DNA replication. Using a FAZF-inducible myeloid cell line, we found that enforced expression of FAZF was accompanied by accumulation in the G1 phase of the cell cycle followed later by apoptosis. These results suggest an essential role for FAZF during the proliferative stages of primitive hematopoietic progenitors, possibly acting in concert with (a subset of) the Fanconi anemia proteins.

FAZF1 (also known as TZFP (1) and murine homologs ROG (2) and Tzfp (3)), a new member of the BTB/POZ (pox virus and zinc finger) protein family, was identified based on its ability to interact with the Fanconi anemia (FA) complementation group C protein, FANCC (4). FA is a genomic instability disorder characterized by progressive pancytopenia, diverse congenital anomalies, and predisposition to cancer, particularly acute myeloid leukemia and squamous cell carcinoma (for review, see Ref. 5). Congenital malformations in FA are a striking feature of the disease. The most common are defects in the thumbs (e.g. absent, bifid, or hypoplastic thumb) (6), although abnormalities are variable and may involve any major organ system. The range and type of developmental defects observed suggest that FA genes are involved in morphogenesis. Cells from FA patients are hypersensitive to DNA cross-linking agents such as mitomycin C. In addition, FA cells have an abnormal cell cycle profile, and this abnormality is exacerbated by treatment with mitomycin C (7). CD34+ cells isolated from FA-C patients fail to thrive in vitro (8, 9), and treating normal CD34+ cells with antisen oligonucleotides directed against the FANCC gene recapitulates the defective phenotype (10). These results suggest that FA genes are involved in ensuring the proper growth and differentiation of primitive hematopoietic cells. Despite efforts to discover the function of the FANCC protein and the function of the proteins encoded by the other more recently cloned FA genes (FANCA, FANCD2, FANCE, FAZF, and FANCG), the basic defect is still unknown (11). There is strong evidence that several FA proteins functionally interact within a large protein complex, and recent experiments demonstrated that the Fanconi anemia protein FANCD2 is coupled to a DNA damage response pathway involving BRCA1 (12).

We reported previously that FAZF is a transcriptional repressor belonging to the BTB/POZ family of proteins and is similar to the PLZF protein (4). PLZF is involved in reciprocal chromosomal translocations with the retinoic acid receptor α leading to a form of acute promyelocytic leukemia (for review, see Melnick and Licht (13)). PLZF is a sequence-specific transcriptional repressor that functions by interacting with corepressor complexes including HDAC1. Enforced expression of PLZF in the murine hematopoietic cell line 32Dcl3 blocks cells in G0/S phase, inhibits cell growth and differentiation, and leads to apoptosis (14). Experiments with PLZF nullizygous mice showed that it is essential for axial skeleton patterning and normal limb development (15).

There are many unanswered questions regarding the function of FAZF in hematopoiesis and its relationship to the pathogenesis of FA, including its expression profile and its effects on growth and differentiation in hematopoietic cells. In the present study, we show that FAZF mRNA and protein are expressed in primary hematopoietic CD34+ progenitor cells, increase during early proliferation, and are then down-regulated.
during terminal differentiation in both erythroid and myeloid lineages. The pattern is similar but not identical with that of PLZF. Further analysis using a FAZF-inducible hematopoietic cell line demonstrated that enforced expression of FAZF triggers a G1 phase cell cycle arrest followed by increased apoptosis. Thus, our data suggest that FAZF influences hematopoietic cell fate, and its effects are conditional, depending on the proliferation/differentiation status of the cell.

**EXPERIMENTAL PROCEDURES**

**Plasmids, Antibodies, Cytokines, Viruses, and Chemicals** — The pFLAG-FAZF expression plasmid and 293-EBNAPFLAG-FAZF cell line have been described (4). FAZF-specific antibodies were prepared using a FAZF-glutathione S-transferase fusion protein as an antigen, essentially as described previously (16). The glutathione S-transferase-FAZF expression plasmid was constructed by inserting an internal XhoI-BamHI fragment from FAZF cDNA, encoding amino acid residues 114–295 of the FAZF protein, into an XhoI-BamHI-cut pGEX-5x-2 vector (Amersham Biosciences). U937/FAZF cells, a line of U937 cells stably expressing FAZF and the autoregulatory tet-VP16 under the control of the tet-operator promoter (17), were routinely maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 0.5 mg/ml puromycin, and 0.1 μg/ml tetracycline in 5% CO2. Recombinant human Epo was purchased from Amgen Corp. (Thousand Oaks, CA) and used at 1 unit/ml. Recombinant human SLF and granulocyte-CSF were purchased from R&D Systems (Minneapolis, MN) and used at 50 and 10 ng/ml, respectively. Recombinant human GM-CSF and IL-3 were gifts from Immunex Corp. (Seattle, WA) and used at 200 units/ml each. Monoclonal mouse anti-PLZF antibody was purchased from Oncogene Research Products (Cambridge, MA). All other antibodies and chemicals were obtained from Sigma unless otherwise indicated.

**Construction of Inducible Cell Lines** — Tetracycline-inducible FLAG-tagged FAZF cell lines were produced using the Tet-off system (18). Briefly, an EcoRI/BglII fragment containing FAZF cDNA was obtained from pSGS-FAZF (4) and cloned into pUHD10-3 cut with EcoRI and BamHI. After transfection, 293 EBNA cells were washed once and resuspended in 400 μl of additive-free RPMI 1640. Ten micrograms of pUHD:FAZF and 1 μg of pIND (Invitrogen), as a neomycin selection marker, were linearized and co-transfected by electroporation at 960 microfarads and 0.17 kV using a BioRad electroporator. After 24 h, cells were plated into methycellulose containing 10% fetal bovine serum, 0.1 μg/ml tetracycline, and 0.5 μg/ml puromycin with 1 mg/ml G418, 1 μg/ml Ganciclovir, and 1 μg/ml puromycin. Growth of triplicate cultures of U937 cells was measured by the metabolic conversion of tetrazolium to formazan (CellTiter 96 Proliferation Assay, Promega).

**Separation and Culture of CD34 Cells** — Mononuclear cells were obtained using Ficol-Hypaque centrifugation from normal human umbilical cord blood. CD34 cells were isolated and magnetically separated using magnetic cell separation beads (Miltenyi Biotech Inc., Auburn, CA) according to the instructions of the manufacturer. The purification method routinely gave CD34 cells that were more than 80–95% pure, as previously described (19, 20). CD34 cells were cultured either in suspension culture or semi-solid culture for differentiation as previously described (19–22). Briefly, 200 cells/ml were seeded in semisolid cultures containing Iscove’s modified Dulbecco’s medium (Invitrogen), 1% methylcellulose, 30% fetal calf serum, 0.1 mmol/liter hemin (Eastman Kodak Co.), 2 mmol/liter L-glutamine (Invitrogen), 0.1 mmol/liter β-mercaptoethanol, 200 units/ml granulocyte-macrophage-CSF, 200 units/ml IL-3, 50 ng/ml IL-6, 1 units/ml Epo, 10 μg/ml vitamin B12, 15 μg/ml folic acid, and 10 μg/ml insulin. For erythroid differentiation in suspension culture, CD34 cells were seeded at 2 x 104 cells/ml in Iscove’s modified Dulbecco’s medium containing 15% fetal calf serum in the presence of IL-3, granulocyte-macrophage-CSF, SLF, and Epo. For myeloid differentiation, CD34 cells were cultured either in suspension or methylcellulose culture for CFU-granulocyte macrophage as erythroid or myeloid lineages except with the addition of 10 ng/ml granulocyte-CSF in lieu of Epo.

**Reverse Transcriptase-PCR Analysis** — Total RNA was isolated from freshly separated CD34 cells (d0) or differentiated cells in both erythroid and myeloid lineages at different time courses (d3-d14) by Qiagen RNeasy mini kits (Qiagen, Valencia, CA) as suggested by the manufacturer. Total RNA was treated with DNase I for 15 min at room temperature followed by heating at 95 °C for 10 min before reverse transcription to eliminate any contamination of remaining genomic DNA. PCR was performed by a thermal cycler (PerkinElmer Life Sciences). The sequences of primers are as follows: FAZF, 5’-GAG ATG TCG CAC AAG CAC TCG C-3’, 5’-CAA CTG GTT CGT GCT CCA GAG C-3’, PLZF, 5’-GGA GCA TTC CAG CAG CCA GA-3’, 5’-GGA GTA GAT GGC CAG ATG CT-3’. The primers for β-actin were described previously (20). The PCR profile used was denaturation at 94 °C for 45 s, annealing at 52–55 °C for 45 s, and polymerization at 72 °C for 2 min for 35 cycles. To measure proliferation rates, cells were transfected with stable expression constructs, transfected to membrane, and hybridized with [3H]labeled FASP (Amershams Biosciences)-labeled FAZF, PLZF, or β-actin gene fragment as a probe. Hybridization was performed overnight at 42 °C, filters were washed with 0.1 x SSC (1 x SSC = 0.15 μM NaCl and 0.015 μM sodium citrate), 0.1% SDS at 55 °C for 60 min, dried, and exposed to x-ray at −70 °C.

**Immunoblotting** — Whole cell lysates were prepared by suspending cells at a concentration of 2 x 107 cells/ml in cell lysis buffer (50 mmol/liter Tris, pH 7.4, 0.25 mmol/liter NaCl, 0.5% Nonidet P-40, 0.1% SDS, 1 mmol/liter phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 100 mmol/liter NaF). Protein in the clear lysate was quantitated using the Bio-Rad protein assay kit and separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins were electroblotted onto Immobilon-P membranes (Millipore Corp., Bedford, MA) and incubated with mouse or rabbit antibodies specific for PLZF, FAZF, FLAG M2, or actin, as noted in text, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies. Proteins were detected with the ECL-Western blotting system (Amersham Biosciences).

**Cell Cycle Analysis** — Cells were seeded at a density of 5 x 104 cells/ml in RPMI 1640 plus 10% fetal calf serum and incubated for 1–7 days in 5% CO2 at 37 °C. Cells were washed in phosphate-buffered saline (PBS) and fixed in 70% cold ethanol at −20 °C, washed twice in PBS, and incubated in 50 μg/ml RNase A and 20 μg/ml propidium iodide for 30 min at 37 °C. The cell cycle status was detected by fluorescence-activated cell sorter flow cytometry and analyzed using CellFit software (BD Pharmingen).

**Apoptosis Assays** — Apoptosis was determined using annexin V staining. Briefly, cells were incubated with annexin V-fluorescein isothiocyanate in binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) for 15 min at room temperature, then suspended in binding buffer containing 50 μg/ml propidium iodide followed by flow cytometry analysis.

**Immunofluorescence Microscopy** — For FAZF expression in 293 EBNA cells (Invitrogen), cells were seeded on chamber slides and transfected using LipofectAMINE as directed by the manufacturer (Invitrogen). Plasmids encoding epitope-tagged FAZF or the parental vectors as negative controls for antibody specificity were used as indicated in text. Cells were processed as described previously (4) using monoclonal anti-ha 12CA5 (Roche Molecular Biochemicals) and/or rabbit polyclonal FAZF antibodies (Amersham Biosciences, Corp. South San Francisco, CA) and Oregon Green-conjugated goat anti-mouse and/or Texas Red-conjugated goat anti-rabbit (Molecular Probes, Eugene, OR) as secondary antibodies. For analysis of CD34 cells, cells were placed on chamber slides pretreated with poly-L-lysine. Sites of DNA synthesis were determined by a 2-bromo-2-deoxy-uridine (BrdUrd)-labeling kit (Roche Molecular Biochemicals). Briefly, cells were incubated in the presence of 10 μM BrdUrd for 4.5 h, permeabilized, and fixed with 70% ethanol in a 50 mM glycine buffer, pH 2.0. Cells were incubated with rabbit FAZF-specific antisera followed by Texas Red-conjugated goat anti-rabbit (Molecular Probes). BrdUrd incorporation was visualized with an anti-BrdUrd mouse monoclonal antibody followed by a fluorescein-labeled secondary antibody. Image collection and manipulation for overlapping signals were performed as described previously (4).

**RESULTS**

**FAZF Localizes in Foci in Human Hematopoietic Progenitor Cells** — To determine the subcellular localization of FAZF we generated FAZF-specific antibodies using a glutathione S-transferase-FAZF fusion protein as an antigen. An internal domain of FAZF with only 14% identity to PLZF was selected to reduce potential cross-reactivity with PLZF and other BTB/POZ proteins. To demonstrate that the antibody recognizes FAZF, we examined lysates from 293 EBNA cells transiently transfected with a plasmid encoding FLAG-tagged FAZF (293/ F1-FAZF) or the parental plasmid (control) by immunoblot. As shown in Fig 1A, the antibody recognizes FAZF, and no signal was observed in negative control lysates. Reprobing the blot with anti-FLAG detected a band overlapping with that recognized by anti-FAZF (Fig 1B). In immunofluorescence assays
FAZF and Hematopoiesis

using 293/Fl-FAZF cells, preimmune serum lacked specific staining (Fig 1C), whereas FAZF-specific antiserum demonstrated that FAZF is localized in the nucleus of 293/Fl-FAZF cells in speckles in a range of sizes from micropunctate to large foci (Fig 1D). The staining is indistinguishable from that using an anti-FLAG antibody that recognizes the epitope-tagged FLAG-FAZF (4). We conclude that our antibody recognizes FAZF in both immunoblot and immunofluorescence assays.

To determine the expression pattern of endogenously expressed FAZF, CD34+ cells were isolated from human cord blood and grown in the presence of growth factors as described under “Experimental Procedures.” The cells were fixed and stained with anti-FLAG and examined by immunofluorescence. As shown in Fig 2, FAZF is expressed in the nucleus in a speckled pattern, consistent with the pattern observed in 293 cells overexpressing the FLAG epitope-tagged FAZF (4). The speckled pattern is similar to that observed for other BTB/POZ-containing proteins including the related proteins, PLZF (23) and BCL6 (also known as LAZ3) (24, 25).

Endogenous FAZF Associates with Replication Foci in Primary Cells—The significance of the nuclear speckled pattern observed for certain BTB/POZ-containing proteins is unknown. However, recent experiments with BCL6 by Albagli et al. (25) demonstrate a close association of BCL6 and replication foci, suggesting that BCL6 may have a positioning or assembly role in replication. To test the possibility that FAZF associates with sites of DNA synthesis, we examined CD34+ cells that were grown in the presence of erythroid factors for 5 days by pulse-labeling the sites of DNA synthesis with BrdUrd. Stained cells were examined by confocal microscopy. Fig 3 shows that FAZF and BrdUrd labeling occur in foci and that these foci are often adjacent or overlapping, suggesting that FAZF is localized near sites of DNA replication.

FAZF Is Expressed during Erythroid and Myeloid Differentiation of Human Hematopoietic Progenitor Cells—To begin to define the role of FAZF in hematopoiesis, we determined the expression of FAZF during early proliferation and terminal differentiation stages of CD34+ progenitor cells directed to either erythroid or myeloid lineages by the presence of SLF, IL-3, granulocyte, macrophage-CSF, plus Epo (for erythroid) or granulocyte-CSF (for myeloid). The day-7–14 BFU-E (burst-forming unit-erythrocyte)-derived cells were described (19), and CFU-granulocyte macrophage-derived cells expressed myeloid lineage markers such as CD11b/CD14 by flow cytometry analysis (data not shown). The day-3 and -5 suspension culture-derived cells for both erythroid and myeloid lineages can form secondary CFU-erythrocyte and CFU-granulocyte macrophage colonies (data not shown), indicating that the cells differentiate to specific erythroid or myeloid lineages under these culture conditions. The expression of FAZF was compared with that of PLZF, the closest hematopoietic counterpart to FAZF.
Regulation of both PLZF and FAZF is required for the body. We selected two clones with tight regulation and high antibody followed by a peroxidase-conjugated secondary antibody. FAZF upon tetracycline withdrawal was assessed in each independent clone by immunoblot with an anti-FAZF polyclonal antibody. Transcripts from the time points as indicated. Panel B, cell lysates were subjected to SDS/PAGE, and immunoblots were performed by using anti-FAZF or anti-PLZF antibodies. An actin immunoblot was used as a protein loading control.

Cell samples collected at days 0, 3, 5, 7, 10, and 14 were assayed for FAZF or PLZF protein by immunoblot using anti-actin as a control for protein loading. Transcripts from corresponding samples were also analyzed by reverse transcriptase-PCR. As shown in Fig. 4A, PLZF mRNA was expressed in CD34+/H11001 cells grown for 3 and 5 days, and from colonies grown in 1% methyl cellulose cultures for 7, 10, 12, and 14 days in the presence of SLF, IL-3, granulocyte, macrophage-CSF, and with Epo (for erythroid differentiation) or granulocyte-CSF (for myeloid differentiation). Panel A, reverse transcriptase (RT)-PCR amplification was performed on total RNA prepared from the time points as indicated. Panel B, cell lysates were subjected to SDS/PAGE, and immunoblots were performed by using anti-FAZF or anti-PLZF antibodies. An actin immunoblot was used as a protein loading control.

**DISCUSSION**

FAZF was identified as an interacting partner of the Fanconi anemia protein FANCC by a yeast two-hybrid assay, subcellular colocalization, and coimmunoprecipitation (4). FAZF also interacts with another FA protein, FANCG, in yeast two-hybrid and in coimmunoprecipitation experiments, reinforcing the notion that FAZF might be part of the FA protein complex (26).
Because so little is known about the function(s) of FAZF or of the FA proteins, the current work is focused on the basic biology of FAZF, emphasizing early hematopoiesis. We chose to examine hematopoietic progenitor cells because this compartment is a likely intersection between FAZF and FANCC function, based on the structural similarity of FAZF to PLZF and on the pancytopenia observed in FA. To analyze role of FAZF in early hematopoiesis, we determined expression at the mRNA and protein levels, determined subcellular localization, and measured the effects of its enforced expression. A unique aspect
of our work is that these experiments were performed in primary cells as well as with a FAZF-inducible cell line. As a result, we had the opportunity to observe that the effects of FAZF protein expression depended on the differentiation stage of the cells. Our results support the hypothesis that FAZF and PLZF have similar but non-overlapping characteristics and that FAZF plays a role in cell fate decisions during normal hematopoiesis.

We found that expression of FAZF protein in quiescent CD34\(^+\) cells was reproducibly lower than that in proliferating derivatives, whereas PLZF was highly expressed in both quiescent and proliferating stages of CD34\(^+\) cells. Both FAZF and PLZF are expressed at high levels between days 3 and 7 and then decline. As protein expression begins to decrease for PLZF in both erythroid and myeloid lineages, PLZF mRNA is still abundant. Thus, our data suggest that unlike FAZF, PLZF is post-transcriptionally regulated in both myeloid and erythroid lineages as CD34\(^+\) cells proliferate and express their commitment to differentiate. The overlapping expression pattern during early proliferation and late differentiation stages of primary CD34\(^+\) cells between FAZF and PLZF suggests that FAZF expression must decrease to allow for the normal differentiation program. These conclusions are in agreement with those made previously for PLZF using a PLZF-inducible cell line (14, 27).

Like PLZF, FAZF is localized in discrete nuclear foci of various sizes in an asynchronous population of hematopoietic progenitors. BCL6, another BTB/POZ protein, which is involved in translocations frequently found in non-Hodgkin lymphomas (28, 29), is also located in distinct nuclear foci in osteosarcoma cells (24). BCL6 and PLZF proteins function by interacting with co-repressor complexes including histone deacetylase. Recent evidence suggests that BCL6 foci coincide or are nearby DNA replication foci, suggesting that this structurally related transcriptional repressor is involved in some processes related to DNA synthesis (25). The functional significance of the foci is unknown, although BCL6 derivatives lacking the BTB/POZ domain fail to form foci, do not associate with ongoing DNA synthesis, and also fail to function as transcriptional repressors (24). Because FAZF can associate with sites of DNA synthesis, FAZF may have a role in DNA repair processes that occur during replication. In this regard, the recent work by Garcia-Higuera et al. (12) demonstrating the DNA damage-induced co-localization of FANCD2 and BRCA1 in nuclear foci is especially intriguing. BRCA1, a protein with multiple functions involved in the maintenance of genomic stability, has been shown to associate with components of the histone deacetylase complex (30). Further underscoring the possible connection between FA proteins and chromatin remodeling, recent work by Otsuki et al. (31) demonstrate that FANCA interacts with the BRG1 gene product, a subunit of the SWI/SNF chromatin remodeling complex.

The strong homology between FAZF and PLZF and our initial work demonstrating an overlap in transcriptional repression activity suggested that the function of FAZF and PLZF were related. Based on previous experiments with PLZF, we
hypothesized that enforced expression of FAZF would have a profound effect on cell cycle progression, differentiation/proliferation, and apoptosis (14, 27). When expression was induced in the cell lines, FAZF acted as an effective negative regulator of cell growth. Cell cycle analysis of the U937T/FAZF cell lines 3 days after FAZF induction demonstrated that the cells accumulated in the G1 phase of the cell cycle in significant numbers. Moreover, the accumulation in G1 presaged a shift to apoptosis, with apoptotic cells beginning to rise at day 4 post-induction to 32.8% of the cell population at day 7 post-induction.

One major conclusion that can be drawn from our studies comparing FAZF-inducible cell lines and physiologic expression of FAZF in CD34⁺/H11001 cells is that the high physiologic expression of FAZF (and PLZF) in CD34⁺ (days 3–7) cells is compatible with rapid growth in these cells. In contrast, FAZF expression in U937T/FAZF cells has the effect of rapidly causing G1 accumulation followed by apoptosis. One might have concluded from enforced (inducible) expression that PLZF and FAZF have negative growth effects, as reported earlier for PLZF and BCL-6 (14, 24). However, because our studies show that the expression of FAZF and PLZF is abundant in rapidly proliferating derivatives of CD34⁺ cells, this effect apparently depends on the cell type where FAZF and PLZF are expressed. A possible mechanism for these different effects is that repression of critical target genes required for growth suppression might not occur in the CD34⁺ cells because certain differentiation stage-specific co-repressors are absent. Alternatively, the action of certain specific corepressors could be consistent with survival and proliferation of CD34⁺ cells. Specific co-repressors for BTB/POZ-containing proteins are possible in addition to the HDAC1-containing corepressor complex that interacts with (among others) PLZF and BCL6. Indeed, a specific co-repressor

**FIG. 7.** Enforced FAZF expression results in G1 arrest in U937 cells. Control U937T clone and two FAZF-expressing clones were grown in the presence or absence of tetracycline (Tet). Cell cycle analysis was performed daily over a 7-day period.
has been identified for BCL6 (32). It remains to be seen if FAZF has unique interaction partners that can act as co-repressors or for other functional roles. In this regard, it is interesting to speculate on the contribution of one of the FAZF specific interacting partners, FANCC. FANCC mRNA is expressed in CD34+ cells (33, 34) and is evidently necessary for survival (10). Experiments with CD34+ cells from FA patients as well as evidence from Fancc−/− mouse models reinforces the idea that FANCC is involved in a cross-link damage avoidance pathway FA cells (40), and other work has led to the hypothesis that molecular weight complex with Cdc2 (39). Evidence from co-hematopoietic cells. Specifically, it will be of interest to determine whether FAZF is a member of the FA protein core complex, particularly in early hematopoietic cells. Specifically, it will be of interest to determine whether FAZF, like PLZF, is a component of a high molecular weight complex with Cdc2 (39). Evidence from co-immunoprecipitation studies suggest that binding of FANCC and Cdc2 is required to relieve the cell cycle defect observed in FA cells (40), and other work has led to the hypothesis that FANCC is involved in a cross-link damage avoidance pathway that signals through Cdc2 (41). Recent work by Qiao et al. (42) demonstrates that Fanconi anemia proteins are associated with chromatin and the nuclear matrix in wild-type cells and in FA complementation group D cells but not in cells from FA patients belonging to other complementation groups. This is consistent with the idea that the FA protein complex may have a role in chromatin changes during replication and DNA damage repair. Further studies will focus on the role of FAZF in this process.

REFERENCES

1. Lin, W., Lai, C. H., Tang, C. J., Huang, C. J., and Tang, T. K. (1999) Biochem. Biophys. Res. Commun. 264, 789–795
2. Maw, S. C., Choi, A., Yu, E., Kishikawa, H., and Ho, I. C. (2000) Immunity 12, 323–333
3. Tang, C. J., Chuang, C. K., Hu, H. M., and Tang, T. K. (2001) J. Biol. Chem. 276, 19631–19639
4. Haotlin, M. E., Zhi, Y., Ball, H., Silvey, K., Melnick, A., Stone, S., Arai, S., Hawe, N., Owen, G., Zelent, A., and Licht, J. D. (1999) Blood 94, 3737–3747
5. Joenje, H., and Piel, K. J. (2001) Nat. Rev. Genet. 2, 446–457
6. De Kerviler, E., Guermazi, A., Zeldinska, A. M., Gluckman, E., and Frija, J. (2000) Clin. Radiol. 55, 340–345
7. Haneline, L. S., Broxmeyer, H. E., Cooper, S., Hangor, G., Carreau, M., Buchwald, M., and Clapp, D. W. (1998) Blood 91, 4092–4098
8. Walsh, C. E., Nienhuis, A. W., Samulski, R. J., Brown, M. G., Miller, J. L., Young, N. S., and Liu, J. M. (1994) J. Clin. Invest. 94, 1440–1448
9. Walsh, C. E., Grompe, M., Vanin, E., Buchwald, M., Young, N. S., Nienhuis, A. W., and Liu, J. M. (1994) Blood 84, 453–459
10. Segal, G. M., Magenis, E. R., Brown, M., Kebbel, W., Smith, T. D., Heinrich, M. C., and Bagby, G. C., Jr. (1994) J. Clin. Invest. 94, 846–852
11. Timmers, C., Taniguchi, T., Hejna, J., Reifsteck, C., Lucas, L., Bruun, D., Thayler, M., Cox, B., Olson, S., D’Andrea, A. D., Moses, R., and Grompe, M. (2001) Mol Cell 7, 241–248
12. Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M. S., Timmers, C., Hejna, J., Grompe, M., and D’Andrea, A. D. (2001) Mol. Cell 7, 249–262
13. Melnick, A., and Licht, J. D. (1999) Blood 93, 351–356
14. Shkkov, R., Yeyati, P. L., Ivins, S., Melnick, A., Lempert, C., Waxman, S., Zelent, A., and Licht, J. D. (1998) Mol. Cell. Biol. 18, 5533–5545
15. Barna, M., Hare, N., Niwander, L., and Pondulke, P. P. (2000) Nat. Genet. 23, 166–172
16. Hoatlin, M. E., Kerckhaert, J. P., Deweindt, C., Tilly, H., Quief, S., Lecocq, G., and Bastard, C. (1993) Nat. Genet. 5, 66–70
17. Ye, B. H., Lista, F., Lo Coco, F., Knowles, D. M., Offit, K., Changari, R. S., and Dalla-Favera, R. (1993) Science 262, 747–750
18. Yarden, R. I., and Brody, L. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4983–4988
19. Otsuki, T., Turukawa, Y., Ikeda, K., Endo, H., Yamashita, T., Shinozaka, I., Iwamatsu, A., Ozawa, K., and Liu, J. M. (2001) Hum. Mol. Genet. 10, 2651–2660
20. Huyhn, K. D., Fischle, W., Verdin, E., and Bardwell, V. J. (2000) Genes Dev. 14, 1810–1823
21. Brady, G., Billia, F., Knox, J., Huang, T., Kirsch, I. R., Voura, E. B., Hawley, R. G., Cumming, K., Buchwald, M., and Siminovitch, K. (1995) Curr. Biol. 5, 909–922
22. Tower, P. A., Christianson, T. A., Peters, S. T., Ostroski, M. L., Hoatlin, M. E., Zigler, A. J., Heinrich, M. C., Rathbun, R. K., Kebbel, W., Faulkner, G. R., and Bagby, G. C., Jr. (1998) Exp. Hematol. 26, 19–26
23. Carreau, M., Bang, O. J., Liu, L., Edeens, M., Dick, J. E., and Buchwald, M. (1999) Exp. Hematol. 27, 1667–1674
24. Bagby, G. C., Heinrich, M. C., Magenis, E., Brown, M., Kebbel, W., Smith, T. D., and Segal, G. M. (1993) Blood 82, 183 (Abstr. 718)
25. Haneline, L. S., Gobbert, A. T., Ramani, R., Carreau, M., Buchwald, M., Yoder, M. C., and Clapp, D. W. (1999) Blood 94, 1–8
26. Liu, J. M., Young, N. S., Walsh, C. E., Cotterill-Fox, M., Carter, C., Dunbar, C., Barrett, A. J., and Emmons, R. (1997) Hum. Gene Ther. 8, 1715–1730
27. Ball, H. J., Melnick, A., Shakkov, R., Kohnanski, R. S., and Licht, J. D. (1999) Cancer Res. 27, 4106–4113
28. Kupfer, G. M., and D’Andrea, A. D. (1996) Blood 88, 1019–1025
29. Kruyt, F. A., Dijkman, L. M., Arwert, F., and Joenje, H. (1997) Cancer Res. 57, 2244–2251
30. Qiao, F., Mass, A., and Kupfer, G. M. (2001) J. Biol. Chem. 276, 23381–23396
The Effects of the Fanconi Anemia Zinc Finger (FAZF) on Cell Cycle, Apoptosis, and Proliferation Are Differentiation Stage-specific

Mu-Shui Dai, Nathalie Chevallier, Stacie Stone, Michael C. Heinrich, Melanie McConnell, Tanja Reuter, Hal E. Broxmeyer, Jonathan D. Licht, Li Lu and Maureen E. Hoatlin

J. Biol. Chem. 2002, 277:26327-26334. doi: 10.1074/jbc.M201834200 originally published online May 1, 2002

Access the most updated version of this article at doi: 10.1074/jbc.M201834200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 42 references, 22 of which can be accessed free at http://www.jbc.org/content/277/29/26327.full.html#ref-list-1